ClinicalTrials.gg
RecruitingNCT07076524SIGNALUpdated Nov 19, 2026

MuScle WastIng and DysphaGia iN CriticAlly IlL Patients (SIGNAL)

An observational study in Critical Illness, Dysphagia and Muscle Wasting in Critically Ill, sponsored by Barts & The London NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionDeglutition DisordersRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Deglutition Disorders
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Deglutition Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Barts & The London NHS Trust · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Deglutition Disorders with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Deglutition Disorders · United Kingdom.

Planned enrollment
5th of 11
160 · median 113
Started
2025
the only one that year
Observational
11 of 28
2 open now
Registered
27th of 28
by date
Lead sponsor
1 of 28
Barts & The London NHS Trust

Among the 28 studies in Deglutition Disorders with a site in United Kingdom, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2025, is one of 11 observational ones, and was the 27th registered.

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

Browse Deglutition Disorders studies →

Open to participants now

2 of the 28 studies in Deglutition Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Deglutition Disorders with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this study is to find out how muscle wasting in the mouth and throat affects swallowing (dysphagia) in adults who are critically ill and being treated in intensive care units.

The main aims of this research study are to understand: how much and how quickly the oral and suprahyoid muscles waste in critically ill participants, and whether muscle wasting causes problems with swallowing. The investigators will compare critically ill participants with non-critically ill participants to determine if muscle wasting is linked to swallowing problems.

In this study, participants will have the size and strength of their mouth and throat muscles measured at four different times during their critical care admission and hospital stay. Tests will also be performed to check how well and how safely participants can swallow. Tongue strength will be measured, and participants will answer questions about their experience with swallowing and eating using patient-reported outcome measures.

This study may help identify better ways to diagnose and treat swallowing problems in people who are critically ill, to support safe eating and drinking and promote faster recovery.

Read the detailed description

Background:

Dysphagia is a common and serious complication among critically ill patients admitted to intensive care units (ICUs). Up to 62% of patients who require mechanical ventilation experience dysphagia, which can lead to aspiration pneumonia, malnutrition, longer hospital stays, and increased mortality. Muscle wasting is a known consequence of critical illness and is associated with poor functional outcomes. The contribution of oral and suprahyoid muscle wasting to dysphagia in critically ill participants is poorly understood. This study aims to prospectively evaluate muscle wasting and its impact on swallowing function in critically ill adults.

Ethical Approval:

This study has Research Ethics Committee and Health Research Authority approval.

Study Objectives:

Primary Objective:

To measure the extent and rate of change in the cross-sectional area of the oral and suprahyoid muscles in critically ill adults using bedside ultrasound at four time points, and to relate these changes to swallowing physiology and safety.

Secondary Objectives:

To compare muscle mass and swallowing function between critically ill and non-critically ill participants.

To measure electrophysiological features of swallowing muscles using high-definition surface electromyography.

To assess patient-reported outcomes related to swallowing and eating.

To compare changes in the rectus femoris (thigh) muscle to those in the oral and suprahyoid muscles as a reference for general muscle wasting.

Study Design:

This is a prospective observational study. Critically ill participants admitted to the ICU will be recruited and compared with non-critically ill controls. The study includes repeated measures of muscle size and swallowing function over time.

Study Procedures:

Ultrasound Assessments:

The cross-sectional area of the tongue, geniohyoid, mylohyoid, and anterior belly of digastric muscles will be measured using bedside ultrasound at four time points during the participant's ICU stay. The rectus femoris muscle will also be measured as a reference for general muscle wasting.

Swallowing Evaluation:

Instrumental assessments of swallowing physiology and safety will be performed using gold standard assessments (e.g., videofluoroscopy or fiberoptic endoscopic evaluation of swallowing).

Tongue Strength:

Tongue strength will be measured using tongue dynamometry.

Electromyography:

High-definition surface electromyography will assess muscle activation patterns at rest and during swallowing.

Patient-Reported Outcomes:

Participants will complete patient reported outcome measures on swallowing, eating, and quality of life.

Data Management and Quality Assurance:

Data will be collected and managed according to Good Clinical Practice (GCP) and UK data protection regulations. Data will be collected using an online database (RedCap). Monitoring and auditing will be conducted by the sponsor to ensure protocol adherence and data integrity.

Sample Size and Statistical Analysis:

The sample size is calculated to detect clinically meaningful differences in muscle wasting and swallowing outcomes, based on expected rates in critically ill patients. Sample size was calculated based on a proof-of-conduct study completed by the investigators.

The primary analysis will use mixed-effects models to evaluate changes in muscle size and their association with swallowing function over time. Secondary analyses will compare critically ill patients with non-critically ill controls and explore associations between muscle wasting, swallowing outcomes, and patient-reported measures. Missing data will be addressed using appropriate statistical methods, such as multiple imputation or sensitivity analyses, as detailed in the statistical analysis plan.

Safety and Adverse Event Reporting:

The study involves only non-invasive assessments; risks are minimal and mainly relate to patient discomfort during swallowing tests. Adverse events and serious adverse events will be monitored and reported according to regulatory requirements.

Patient and Public Involvement:

Patients with experience of dysphagia in critical care contributed to the design of the study and the selection of outcome measures.

03

Conditions studied

  • Critical Illness
  • Dysphagia
  • Muscle Wasting in Critically Ill
  • Swallowing Disorders

Browse trials for

Keywords

  • dysphagia
  • critical illness
  • swallowing disorders
  • muscle wasting
04

In context

Deglutition Disorders Reclassified

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

This study's planned enrollment of 160 is above the median of 91 across 250 observational studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

Barts & The London NHS Trust is the lead sponsor of 152 studies on the registry; 22 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Deglutition Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critically ill patients and non-critically ill patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults >18 years
  • Receiving mechanical ventilation via endotracheal tube and/or tracheostomy. Expected to receive ventilation for at least 72 hours.
  • Expected to survive admission and spend more than 7 days in the intensive care unit.

Control participants

  • Adults >18 years
  • Receiving ward-based care.
  • Expected to survive hospital admission. Present with a primary medical diagnosis of acute medical or surgical illness, not requiring critical care admission.

Exclusion criteria

Exclusion Criteria:

Applies to both critically ill and control participants.

  • Pregnancy
  • Patients with a diagnosis of a primary neuromuscular pathology (e.g., motor neurone disease), central nervous system disease (e.g., stroke, Guillain barre), traumatic brain injury, connective tissue disease (e.g., scleroderma), head and neck cancer, previous surgery or radiotherapy to the head and neck.
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Measure the extent and rate of muscle wasting

    To measure the extent and rate of change in cross-sectional area of the oral and suprahyoid muscles in critically ill adults using bedside ultrasound across four time points. The extent and rate of muscle wasting will be assessed by measuring the change in cross-sectional area (mm²) of the oral and suprahyoid muscles using bedside ultrasound.

    Time frame: Day 1, 3, 7 and 10 of intensive care unit admission

  2. Relate muscle wasting to swallow physiology and safety

    To correlate changes in cross-sectional area to swallow physiology and safety in critically ill patients, using instrumental swallowing evaluations and tongue strength. To quantify the change in size of the oral and suprahyoid muscles, the cross-sectional area (mm²) will be measured using bedside ultrasound. Swallowing physiology and safety will be assessed using instrumental swallowing evaluations (e.g., Fiberoptic Endoscopic Evaluation of Swallowing (FEES)).The correlation coefficient (e.g., Pearson's or Spearman's r) between ultrasound-measured muscle cross-sectional area and instrumental swallowing assessment scores (e.g., the Penetration Aspiration Scale) will be used.

    Time frame: Following day 10 ultrasound or when the patient is extubated and clinically appropriate for swallow assessment

Secondary outcomes

  1. Measure electrophysiological features of swallow muscle activity

    To measure the electrophysiological features of swallowing muscles using high definition surface electromyography in critically ill and non-critically ill patients. Electrophysiological features of swallowing-related muscles will be measured. Parameters will include average root mean square amplitude, symmetry of muscle activation, and duration of muscle activity during swallowing tasks.

    Time frame: Day 1, 3, 7 and 10 of intensive care unit admission

  2. Compare relationship between muscle mass and swallow physiology

    To compare the relationship between muscle mass and swallow physiology in critically ill patients and non-critically ill patients. The correlation between muscle mass and swallow physiology will be assessed. Muscle mass will be measured using ultrasound cross-sectional area (cm²) of the oral and suprahyoid muscles at four time points: Day 1, Day 3, Day 7, and Day 10 of ICU admission. Swallow physiology will be evaluated using instrumental evaluation (e.g., flexible endoscopic evaluation of swallow) and the following scales: Penetration-Aspiration Scale, Yale Pharyngeal Residue Severity Rating Scale and the Dynamic Imaging Grade of Swallow Toxicity) whichever occurs first, and when the patient is deemed clinically appropriate for assessment. The primary outcome will be the correlation coefficient (e.g., Pearson's or Spearman's r) between ultrasound-measured muscle mass (cm²) and swallow physiology scores.

    Time frame: Day 1, 3, 7 and 10 ultrasound assessments, swallow evaluation completed following day 10 ultrasound or when patient is extubated and clinically appropriate

  3. Patient reported outcomes: Sydney Swallow Questionnaire

    Patient-reported severity of dysphagia symptoms will be assessed using the Sydney Swallow Questionnaire (SSQ), with the total score ranging from 0 to 1700, where higher scores indicate greater symptom severity.

    Time frame: Within two weeks of day 10 ultrasound measurement or when clinically appropriate (e.g., ICU delirium resolved if present), up to 1 month

  4. Patient reported outcomes: Swallowing Quality of Life (SWAL-QoL) Score

    Patient-reported swallowing-related quality of life will be assessed using the Swallowing Quality of Life (SWAL-QoL) questionnaire, a 44-item instrument producing a total score from 0 to 100, where higher scores reflect better quality of life.

    Time frame: Within two weeks of day 10 ultrasound measurement or when clinically appropriate (e.g., ICU delirium resolved if present), up to 1 month

  5. Patient reported outcomes: Functional Oral Intake Scale

    Functional oral intake level will be measured using the Functional Oral Intake Scale (FOIS), a 7-point ordinal scale ranging from 1 (nothing by mouth) to 7 (total oral diet with no restrictions), where higher scores represent greater functional intake.

    Time frame: Within two weeks of day 10 ultrasound measurement or when clinically appropriate (e.g., ICU delirium resolved if present), up to 1 month

  6. Patient reported outcomes: Eating Assessment Tool-10 (EAT-10)

    Patient-reported dysphagia symptom burden will be screened using the Eating Assessment Tool-10 (EAT-10), a 10-item instrument with total scores ranging from 0 to 40, where scores of 3 or higher suggest abnormal swallowing.

    Time frame: Within two weeks of day 10 ultrasound measurement or when clinically appropriate (e.g., ICU delirium resolved if present), up to 1 month

  7. Compare the extent of muscle wasting in critically ill versus non-critically ill patient

    To measure and compare the extent and rate of change in cross-sectional area of the rectus-femoris muscle and the oral and supra-hyoid muscles using bedside ultrasound across four time points.

    Time frame: Day 1, 3, 7 and 10 ultrasound evaluation vs single timepoint in non-critically ill patients

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2028, 29 months after the start.

Of 116 non-industry observational studies under Deglutition Disorders, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 52. This study's planned 29 months is above that.

Counting every sponsor, half of 119 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jul 22, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07076524
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Aug 1, 2025
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion